Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Cost-effectiveness of screening for NAFLD in patients with T2D

The authors hypothesized that screening for NAFLD in type 2 diabetes (T2D) patients, starting with ultrasound (US) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST), followed with non-invasive testing for fibrosis to detect those most likely to have fibrosis stage ≥F2, is more cost effective than not screening this population...
Read MoreCost-effectiveness of screening for NAFLD in patients with T2D

NAFLD fibrosis and bone mineral density in diabetic postmenopausal women

X. Zhu et al. (Division of Digestive and Liver Diseases, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, California) aimed to evaluate the association of NAFLD-associated hepatic fibrosis with bone mineral density in postmenopausal women with type 2 diabetes mellitus or impaired glucose regulation...
Read MoreNAFLD fibrosis and bone mineral density in diabetic postmenopausal women

NASH clinical trials during the SARS-CoV-2 pandemic

As the COVID-19 continues to pose extreme challenges to healthcare systems, it is becoming impossible to avoid the overlap between COVID-19 and NASH pandemics. Numerous trials are being conducted despite the crisis and the COVID-19 pandemic has disrupted many aspects of NASH clinical trials, such as patient recruitment, administration...
Read MoreNASH clinical trials during the SARS-CoV-2 pandemic

COVID-19: incidence in patients with metabolic syndrome and NASH

Although a relationship between metabolic syndrome and COVID-19 severity might exist, it is currently unclear whether NASH is associated with a higher risk of SARS-CoV-2 infection. The primary objective of this study by S. Ghoneim et al. (Department of Internal Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA) was to identify...
Read MoreCOVID-19: incidence in patients with metabolic syndrome and NASH

Weight gain and risk of NAFLD: the Nurses’ Health Study II cohort

besity has been identified as a major risk factor for the development of Non-alcoholic fatty liver disease (NAFLD). However, the influence of dynamic changes in adiposity over the life course on NAFLD risk remains poorly understood. MN Kim et al. collected data from 110,054 women enrolled in the Nurses’ Health Study II cohort. They documented...
Read MoreWeight gain and risk of NAFLD: the Nurses’ Health Study II cohort

Economic and Clinical Burden of NASH in T2D patients in the U.S.

Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes mellitus. Patients with both T2DM and NASH have increased risk for adverse clinical outcomes, leading to higher risk for mortality and morbidity. Using a Markov model with 1-year cycles...
Read MoreEconomic and Clinical Burden of NASH in T2D patients in the U.S.

NAFLD cirrhosis: a predictive model of liver decompensation

Non-alcoholic fatty liver disease (NAFLD) has become the most frequently encountered chronic liver disease and is an increasingly important cause of liver cirrhosis as well as other adverse events. The authors of this article retrospectively developed and validated a model to predict hepatic decompensation in NAFLD patients with cirrhosis and compared...
Read MoreNAFLD cirrhosis: a predictive model of liver decompensation